Please ensure Javascript is enabled for purposes of website accessibility

Why Agile Therapeutics Stock Is Crashing Today

By George Budwell - Mar 9, 2020 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech stock is getting hit hard by the marketwide downturn today. Here's why.

What happened

Agile Therapeutics (AGRX -45.03%), like almost all small-cap biotech stocks, is having a really bad Monday. Shares of the early commercial-stage company are down 11.7% as of 10:46 a.m. EDT. 

The culprit? The entire market is taking a step backwards today in response to the rapid spread of the novel coronavirus. Small-cap biotechs like Agile are taking a particularly hard hit because of their need to tap the public markets for capital on a regular basis. In short, it may become much harder to raise capital via secondary offerings if the global economy does indeed slip into a recession due to this deadly respiratory illness. 

The steep plunge in crude oil prices is only adding to investors' unease. 

A man wrapped in a blanket sneezing into a tissue while sitting on a couch.

Image source: Getty Images.

So what

Less than a month ago, Agile got the green light from the Food and Drug Administration for its weekly contraceptive patch dubbed Twirla. Not long thereafter, the company raised roughly $45 million in gross proceeds through a public offering of its common stock to fund Twirla's commercial launch. While this capital raise was a step in the right direction from a liquidity standpoint, Agile may still not have enough in the bank to fully fund Twirla's commercialization. In other words, the company will more than likely need to issue another offering within the next 12 months. Agile, after all, isn't expected to become cash flow positive anytime soon. The problem is that there's no telling what kind of shape the capital markets will be in a year from now. 

Now what

Is this double-digit drop a buying opportunity? It all depends on your view of Twirla. If demand is strong, Agile should be an outstanding growth stock over the long term. Then again, there's always a big question mark when it comes to small-cap biopharmas undertaking the commercialization of their first product. More often than not, things don't go smoothly. As such, this stock arguably only belongs in your portfolio if you are very comfortable with risk and volatility.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agile Therapeutics, Inc. Stock Quote
Agile Therapeutics, Inc.
$0.64 (-45.03%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.